Fasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee). It is grouped under the following drug class(es): Bradykinin B2 receptor antagonists. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include Fasitibant ion and Fasitibant cation. Its PubChem CID is 11498853.
Fasitibant
| CAS No | 869939-83-3 |
|---|---|
| Molecular Formula | C36H49Cl2N6O6S+ |
| Molecular Weight | 764.8 g/mol |
| Synonyms | [(4S)-4-amino-5-[4-[4-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylamino]oxane-4-carbonyl]piperazin-1-yl]-5-oxopentyl]-trimethylazanium |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Fasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee). It is grouped under the following drug class(es): Bradykinin B2 receptor antagonists.
The listed CAS number is 869939-83-3.
The listed molecular formula is C36H49Cl2N6O6S+.
The listed molecular weight is 764.8 g/mol.
[(4S)-4-amino-5-[4-[4-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylamino]oxane-4-carbonyl]piperazin-1-yl]-5-oxopentyl]-trimethylazanium.
The source lists Fasitibant ion and Fasitibant cation.